Tags Archives: acute respiratory distress syndrome (ARDS)

Perfusfind S.L.

Abstract Venovenous extracorporeal membrane oxygenation (VV ECMO) has been used to treat severe coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome; however, patient selection criteria have evolved throughout the pandemic...

Perfusfind S.L.

Abstract In patients with the acute respiratory distress syndrome (ARDS), lung imaging is a fundamental tool in the study of the morphological and mechanistic features of the lungs. Chest computed..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) is increasingly being used for patients with severe respiratory failure and has received particular attention during the coronavirus disease 2019 (COVID-19) pandemic. Evidence from two..

Perfusfind S.L.

Abstract Background Severe COVID-19 induced acute respiratory distress syndrome (ARDS) often requires extracorporeal membrane oxygenation (ECMO). Recent German health insurance data revealed low ICU survival rates. Patient characteristics and experience..

Perfusfind S.L.

Abstract Veno-venous extracorporeal membrane oxygenation is indicated in patients with acute respiratory distress syndrome and severely impaired gas exchange despite evidence-based lung protective ventilation, prone positioning and other parts of..

Perfusfind S.L.

Abstract Acute Respiratory Distress Syndrome (ARDS) accounts for 10% of ICU admissions and affects 3 million patients each year. Despite decades of research, it is still associated with one of..

Perfusfind S.L.

Abstract Background Extracorporeal Membrane Oxygenation (ECMO) therapy for respiratory failure is an increasingly popular modality of support. Patient selection is an important aspect of outcome success. This review assesses the..

Perfusfind S.L.

Abstract The outcome of patients with coronavirus disease (COVID-19) treated in ICUs is unsatisfying (). Venovenous extracorporeal membrane oxygenation (vvECMO) can serve as a rescue strategy when patients deteriorate during..

Perfusfind S.L.

Abstract Perfluorocarbons are oxygen-carrying, dense liquids initially intended for the use in partial or total liquid ventilation of patients with severe acute respiratory distress syndrome but which did not show beneficial effects in clinical studies...

Perfusfind S.L.

Abstract Background Extracorporeal membrane oxygenation (ECMO) has been used extensively for coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS). Reports early in the pandemic suggested that mortality in patients..

Perfusfind S.L.

Abstract We aimed to evaluate the outcomes of post‑traumatic acute respiratory distress syndrome (ARDS)in young patients with and without Extracorporeal membrane oxygenation (ECMO) support. A retrospective analysis was conducted for..

Perfusfind S.L.

Abstract Background: The benefit of extracorporeal membrane oxygenation (ECMO) for patients with severe acute respiratory distress from coronavirus disease 2019 refractory to medical management and lung-protective mechanical ventilation has not been..

Perfusfind S.L.

Abstract Background A retrospective analysis of SUPERNOVA trial data showed that reductions in tidal volume to ultraprotective levels without significant increases in arterial partial pressure of carbon dioxide (PaCO2) for..

Perfusfind S.L.

Abstract Introduction Extracorporeal Membrane Oxygenation (ECMO) may be used in the setting of pregnancy or the peripartal period, however its utility has not been well-characterized. This study aims to give..

Perfusfind S.L.

Abstract Refractory hypoxemia despite the use of extracorporeal membrane oxygenation (ECMO) for coronavirus disease 2019 (COVID-19)–related acute respiratory distress syndrome remains a challenging problem. A single ECMO circuit may not..

Perfusfind S.L.

Abstract Objectives:  The use of extracorporeal membrane oxygenation (ECMO) in patients with COVID-19 has been supported by major healthcare organizations, yet the role of specific management strategies during ECMO requires..

Perfusfind S.L.

Abstract Coronavirus disease 2019 (COVID-19) has increased the demand for extracorporeal membrane oxygenation (ECMO) and introduced distinct challenges to patient selection for ECMO. Standardized processes for patient selection amidst resource..

Perfusfind S.L.

Abstract For patients with severe acute respiratory distress syndrome (ARDS), receipt of ECMO(1) may improve survival. During the COVID-19 pandemic, the number of patients with COVID-19 referred for ECMO has..

Perfusfind S.L.

Abstract Background Twenty percent of pediatric patients with BA develop ACLF with increased mortality while awaiting LT. Respiratory complications are common in pediatric ACLF and are associated with increased morbidity..

Perfusfind S.L.

Abstract Venovenous extracorporeal membrane oxygenation (VV-ECMO) has been used during the COVID-19 pandemic to support patients with the most severe cases of COVID-19 acute respiratory distress syndrome (ARDS). The earliest..

Perfusfind S.L.

Abstract Background: Venovenous ECMO is a lifesaving technique for patients with severe respiratory failure. Management of carbon dioxide (CO2) levels at ECMO start is crucial, as recent studies found an association..

Perfusfind S.L.

Abstract Few patients with coronavirus disease 2019–associated severe acute respiratory distress syndrome (ARDS) require veno-venous extracorporeal membrane oxygenation (VV-ECMO). Prolonged VV-ECMO support necessitates repeated oxygenator replacement, increasing the risk for..

Perfusfind S.L.

Abstract Where is the imperceptible difference? With great interest, we read the recent article by Whebell and colleagues [1] and were appealed by the beneficial effect of extracorporeal membrane oxygenation..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) in acute respiratory distress syndrome (ARDS) is used to achieve oxygenation and protect lung ventilation. Near infrared spectroscopy (NIRS) measures cerebral regional tissue oxygenation (rSO2)..

Perfusfind S.L.

Abstract We present a case of acute respiratory distress syndrome (ARDS) secondary to COVID-19 who required venovenous extracorporeal membrane oxygenation (V-V ECMO). Initially, a right ventricular assist device (RVAD), the..

Perfusfind S.L.

Abstract In late 2020, during the second wave of COVID-19 in Germany, we started using the MobyBox, which is a novel fully pneumatically driven ECMO device, on a regular basis..

Perfusfind S.L.

Abstract Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and lung involvement is common. Patients with COVID-19 may progress to acute respiratory distress syndrome..

Perfusfind S.L.

Abstract Background. In this study, we evaluate the previously reported novel Minnesota Score for association with in-hospital mortality and allocation of venovenous extracorporeal membrane oxygenation in patients with acute respiratory..

Perfusfind S.L.

Abstract Bleeding and thromboembolic events are common during veno-venous extracorporeal membrane oxygenation (vvECMO). It is unknown whether these complications are driven by the ECMO system itself, multiorgan-failure, or both. The..

Perfusfind S.L.

This case reports on a 35-year-old female patient with systemic lupus erythematosus who presented to hospital with exacerbated encephalopathy under the assumption of an infection after she was found apathetic,..